What You Need To Know About Liability Protection For COVID-19 Products
Executive Summary
Companies developing medical countermeasures for COVID-19 need to become familiar with divergences in the liability protection offered by different countries with regard to possible safety issues that may arise when products are fast-tracked for public health reasons. By doing so they can adopt a systematic process for prospectively evaluating and managing international risks, say Dan Kracov, Lincoln Tsang and Alexander Roussanov.
You may also be interested in...
No Blanket Immunity For COVID-19 Vaccine Liabilities, Says EU
As the race to develop COVID-19 vaccines continues, EU member states are ready to financially cover certain of the companies’ risks, but not to change the rules on liability. Transparency proponents are calling for all contracts on vaccine purchases to be made public.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.